Lincoln Pharmaceuticals aims to achieve Rs. 750 crore revenue by FY26

Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has entered the elite league of Rs. 1,000 crore plus market capitalization companies for the first time. As per the release, the share price of the company hit a 52 week high of Rs. 503.35 per share on 24 August 2023. Company aims to maintain healthy growth in revenue and margins in the coming years and has set a target of achieving Rs. 750 crore revenue by FY26 while maintaining its ‘Net Debt Free’ status.

For FY23, the company has reported its Best-ever results in a financial year with highest - Revenue, EBITDA and Net Profit. Company achieved a milestone of Rs. 500 crore plus revenue and Rs. 100 crore plus profit before tax for the first time in a financial year.  Company is also ranked among a very few companies to achieve a profit growth every single year from FY13 to FY23. It is among only 16 companies out of 4,200 plus listed companies in the Indian stock exchange to do so as per the analysis of Morningstar. During 10 years from FY13 to FY23, Company has delivered a robust CAGR of over 22% in Net profits, 19% plus in EBITDA and over 10% in Revenue.

Rating agencies, CRISIL has upgraded its ratings on the company's bank facilities to ‘CRISIL A/Stable and CRISIL A1’. In the last one year, share price of the company has gained by over 70% - from Rs. 281.80 per share on 25 August 2022 to Rs. 488.20 per share at close on 24 August 2023. Company currently exports to 60 plus countries and recently started exports to Canada. TGA - Australia and EU GMP approvals will further strengthen the company's presence and expand its network to 90 plus countries.

Post a Comment